IRIS UniCatt

Rossetti, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.740
EU - Europa 1.318
AS - Asia 1.235
SA - Sud America 280
AF - Africa 67
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
Totale 4.650
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.655
SG - Singapore 574
CN - Cina 298
IT - Italia 233
BR - Brasile 226
SE - Svezia 213
FR - Francia 186
DE - Germania 152
PL - Polonia 137
GB - Regno Unito 87
IN - India 87
VN - Vietnam 69
IE - Irlanda 62
ID - Indonesia 51
FI - Finlandia 46
CA - Canada 44
ES - Italia 36
MX - Messico 32
RU - Federazione Russa 31
UA - Ucraina 31
ZA - Sudafrica 25
KR - Corea 20
AR - Argentina 19
HK - Hong Kong 18
PT - Portogallo 18
BD - Bangladesh 17
JP - Giappone 17
AT - Austria 16
BE - Belgio 13
IQ - Iraq 12
LT - Lituania 12
EC - Ecuador 11
NL - Olanda 11
PH - Filippine 11
TR - Turchia 10
CM - Camerun 8
CO - Colombia 8
CL - Cile 7
IR - Iran 7
RO - Romania 7
CH - Svizzera 6
TN - Tunisia 6
TW - Taiwan 6
AE - Emirati Arabi Uniti 5
GR - Grecia 5
UZ - Uzbekistan 5
CI - Costa d'Avorio 4
DZ - Algeria 4
EU - Europa 4
SA - Arabia Saudita 4
VE - Venezuela 4
AU - Australia 3
KE - Kenya 3
LV - Lettonia 3
MA - Marocco 3
PK - Pakistan 3
TH - Thailandia 3
UG - Uganda 3
AO - Angola 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BH - Bahrain 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
JO - Giordania 2
KZ - Kazakistan 2
LB - Libano 2
ML - Mali 2
NG - Nigeria 2
PA - Panama 2
PY - Paraguay 2
AL - Albania 1
AM - Armenia 1
BW - Botswana 1
EG - Egitto 1
GT - Guatemala 1
GY - Guiana 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
MK - Macedonia 1
MM - Myanmar 1
MN - Mongolia 1
MT - Malta 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
SR - Suriname 1
TT - Trinidad e Tobago 1
Totale 4.650
Salva come PNG Salva come JPEG
Città #
Chandler 320
Singapore 264
Ashburn 168
Kraków 108
New York 92
Beijing 70
Milan 66
Dublin 61
Los Angeles 51
Jakarta 42
Jacksonville 40
Redmond 36
San Mateo 36
Boston 33
Rome 31
Hefei 30
London 28
Wilmington 27
Ho Chi Minh City 24
Princeton 24
Ann Arbor 23
Houston 23
Munich 23
Paris 23
Frankfurt am Main 22
Marseille 22
Cattolica 21
Helsinki 21
Warsaw 21
Hanoi 19
Moscow 19
Nanjing 19
Pune 17
Redwood City 17
The Dalles 17
Tokyo 17
Atlanta 16
Dearborn 16
Johannesburg 15
Seattle 15
Catania 14
Chicago 13
Madrid 13
Montreal 13
Brussels 12
Hong Kong 12
Nuremberg 12
São Paulo 12
Dallas 11
Orem 11
Seoul 11
Brooklyn 10
Nanchang 10
Stockholm 10
Vienna 10
Fairfield 9
Kent 9
Manchester 9
Norwalk 9
Ottawa 9
Santa Clara 9
Düsseldorf 8
Lawrence 8
Phoenix 8
Poplar 8
Woodbridge 8
Brasília 7
Bremen 7
Changsha 7
Miami 7
San Francisco 7
Toronto 7
Turku 7
Amsterdam 6
Buffalo 6
Cusano Milanino 6
Davao City 6
Dhaka 6
Hebei 6
Mexico City 6
Porto 6
Queens 6
Turin 6
Washington 6
Boardman 5
Bucharest 5
Charlotte 5
Denver 5
Guangzhou 5
Hangzhou 5
La Habra 5
Lancaster 5
Lappeenranta 5
Mountain View 5
Mumbai 5
Rio de Janeiro 5
Shenyang 5
Tianjin 5
Augusta 4
Bologna 4
Totale 2.398
Salva come PNG Salva come JPEG
Nome #
The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study 462
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 179
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 170
Whole-genome sequencing reveals host factors underlying critical COVID-19 164
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 142
Cognitive reserve and neuropsychological functioning in older HIV-infected people 138
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 130
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 127
An explainable model of host genetic interactions linked to COVID-19 severity 124
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 123
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 121
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 118
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 117
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 117
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 115
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience 112
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 111
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 111
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 110
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 108
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 103
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 97
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 94
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 94
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 88
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 86
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 85
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 85
Treatment of HCV infection with the novel NS3/4A protease inhibitors 84
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 82
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 81
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 80
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 79
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 76
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 76
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 75
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 69
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 69
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 68
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 64
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 60
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 56
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 56
Totale 4.706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.549
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202151 0 0 0 0 0 8 6 2 13 6 12 4
2021/2022269 12 3 4 19 7 12 13 53 10 27 34 75
2022/2023887 96 105 53 116 61 100 32 77 101 70 58 18
2023/2024567 27 108 28 40 36 126 31 25 24 24 39 59
2024/2025923 30 40 91 52 106 43 52 50 99 71 155 134
2025/20261.311 331 51 122 315 464 28 0 0 0 0 0 0
Totale 4.706